亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis

任天堂 吡非尼酮 医学 特发性肺纤维化 内科学 肺活量 荟萃分析 胃肠病学 肿瘤科 扩散能力 肺功能
作者
James Finnerty,Aravind Ponnuswamy,Prosjenjit Dutta,Ammar Abdelaziz,H G Kamil
出处
期刊:BMC Pulmonary Medicine [Springer Nature]
卷期号:21 (1) 被引量:81
标识
DOI:10.1186/s12890-021-01783-1
摘要

Abstract Background Research questions To compare the efficacy of nintedanib and pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of anti-fibrotic therapy (grouping nintedanib and pirfenidone together) in patients with IPF versus patients with progressive lung fibrosis not classified as IPF. Study design and methods A search of databases including MEDLINE, EMBASE, PubMed, and clinicaltrials.gov was conducted. Studies were included if they were randomised controlled trials of pirfenidone or nintedanib in adult patients with IPF or non-IPF patients, and with extractable data on mortality or decline in forced vital capacity (FVC). Random effects meta-analyses were performed on changes in FVC and where possible on mortality in the selected studies. Results 13 trials of antifibrotic therapy were pooled in a meta-analysis (with pirfenidone and nintedanib considered together as anti-fibrotic therapy). The change in FVC was expressed as a standardised difference to allow pooling of percentage and absolute changes. The mean effect size in the IPF studies was − 0.305 (SE 0.043) ( p < 0.001) and in the non-IPF studies the figures were − 0.307 (SE 0.063) ( p < 0.001). There was no evidence of any difference between the two groups for standardised rate of FVC decline ( p = 0.979). Pooling IPF and non-IPF showed a significant reduction in mortality, with mean risk ratio of 07.01 in favour of antifibrotic therapy ( p = 0.008). A separate analysis restricted to non-IPF did not show a significant reduction in mortality (risk ratio 0.908 (0.547 to 1.508), p = 0.71. Interpretation Anti-fibrotic therapy offers protection against the rate of decline in FVC in progressive lung fibrosis, with similar efficacy shown between the two anti-fibrotic agents currently in clinical use. There was no significant difference in efficacy of antifibrotic therapy whether the underlying condition was IPF or non-IPF with progressive fibrosis, supporting the hypothesis of a common pathogenesis. The data in this analysis was insufficient to be confident about a reduction in mortality in non-IPF with anti-fibrotic therapy. Trial Registration PROSPERO, registration number CRD42021266046.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
23秒前
cosine发布了新的文献求助30
30秒前
cosine完成签到,获得积分10
37秒前
gszy1975完成签到,获得积分10
1分钟前
uziMOF发布了新的文献求助10
1分钟前
萧水白应助uziMOF采纳,获得10
1分钟前
xu应助Kapur采纳,获得30
2分钟前
mengyuhuan完成签到 ,获得积分0
2分钟前
Kapur完成签到,获得积分10
2分钟前
3分钟前
llm发布了新的文献求助10
3分钟前
苏满天完成签到 ,获得积分10
3分钟前
行云流水完成签到,获得积分10
3分钟前
嗯哼举报咩咩羊求助涉嫌违规
3分钟前
Hello应助Chenzr采纳,获得10
3分钟前
星辰大海应助科研通管家采纳,获得10
4分钟前
852应助科研通管家采纳,获得10
4分钟前
小乐儿~完成签到,获得积分10
4分钟前
bluebell完成签到,获得积分10
4分钟前
4分钟前
科研搬运工完成签到,获得积分10
5分钟前
5分钟前
风中的惊蛰完成签到,获得积分10
5分钟前
6分钟前
6分钟前
Owen应助Wen采纳,获得10
6分钟前
7分钟前
嗯哼举报哼哼求助涉嫌违规
7分钟前
大个应助木木夕采纳,获得10
7分钟前
火焰向上发布了新的文献求助10
9分钟前
火焰向上完成签到,获得积分10
9分钟前
10分钟前
10分钟前
标致初晴完成签到,获得积分10
10分钟前
jiajia发布了新的文献求助20
10分钟前
10分钟前
10分钟前
Jasper应助dawn采纳,获得10
11分钟前
11分钟前
11分钟前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Semiconductor Process Reliability in Practice 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 600
GROUP-THEORY AND POLARIZATION ALGEBRA 500
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
Days of Transition. The Parsi Death Rituals(2011) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3234564
求助须知:如何正确求助?哪些是违规求助? 2880908
关于积分的说明 8217339
捐赠科研通 2548507
什么是DOI,文献DOI怎么找? 1377807
科研通“疑难数据库(出版商)”最低求助积分说明 648006
邀请新用户注册赠送积分活动 623347